ABR Radiation Oncology Exam Prep

Week 1 — Part 1: Radiobiology 

Difficulty: Heavy — High Yield

What it covers: Part 1 establishes the biological foundation every ABR question rests on. You will master the historical development of radiation oncology and the multidisciplinary team, the direct and indirect mechanisms of radiation-induced DNA damage, the Four Rs of radiobiology, the oxygen effect and tumor hypoxia, the Linear-Quadratic model and α/β ratios, acute versus late effects, tissue-specific radiosensitivity, and the therapeutic window that governs every treatment prescription.

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Lock in the Four Rs of radiobiology before anything else. Repair of sublethal damage between fractions is the reason conventional fractionation spares late-responding normal tissues. Reassortment (redistribution) brings surviving cells into radiosensitive G2/M phases between fractions. Reoxygenation converts hypoxic tumor cells into radiosensitive oxygenated cells as treatment proceeds. Repopulation is the proliferation of surviving tumor (and normal) cells between fractions — the reason head and neck treatment time must be kept short. Every fractionation rationale traces back to one of these four.

☐ Direct versus indirect DNA damage. Roughly two-thirds of biological damage from low-LET radiation (photons, electrons) is indirect, mediated by hydroxyl radicals from water radiolysis — which is why oxygen matters. The Oxygen Enhancement Ratio (OER) for low-LET radiation is 2.5 to 3.0; high-LET radiation (neutrons, alpha particles, heavy ions) produces mostly direct damage and has an OER approaching 1.0. Tumor hypoxia is the clinical reason low-LET beams may fail in large or necrotic tumors, and the biological rationale for proton Bragg-peak and heavy-ion therapy.

☐ Linear-Quadratic Model: know it cold. BED = nd × (1 + d/[α/β]). The α/β ratio defines fraction-size sensitivity. High α/β (~10 Gy): most tumors and acutely-responding tissues — insensitive to fraction-size changes. Low α/β (~3 Gy): late-responding tissues (spinal cord, lung, kidney, brain) — highly sensitive to fraction size, which is why hypofractionation is risky near these structures. Alpha kills alone (single-hit lethal); beta brings a buddy (two sublethal hits combined).

☐ Commit the tissue-sensitivity hierarchy to memory. Bergonié-Tribondeau predicts that actively mitotic, undifferentiated, high-mitotic-future tissues are most sensitive: lymphocytes (most sensitive), ovarian/testicular germ cells, small intestinal crypt cells, mucosal epithelium, endothelium. Most resistant: spinal cord and neural tissue, mature muscle, bone. Acute effects appear in rapidly dividing tissues within days to weeks and are reversible; late effects appear months to years later in slowly dividing tissues and are generally irreversible — and are driven primarily by fraction size, not total dose.

☐ Complete the Practice Questions for Part 1 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Foundations of Radiation Oncology & Radiobiology. Main branches: Historical Milestones & Multidisciplinary Team → DNA Damage (direct vs. indirect, double-strand breaks) → Free Radicals & Oxygen Fixation → The Four Rs (Repair, Reassortment, Reoxygenation, Repopulation) → Oxygen Effect & OER → Low-LET vs. High-LET Radiation → Linear-Quadratic Model & α/β Ratios → Cell Cycle Sensitivity (M/late G2 most sensitive; late S most resistant) → Tissue Sensitivity Hierarchy → Acute vs. Late Effects → Therapeutic Window (TCP vs. NTCP) → Fractionation Schemes (standard, hyper, hypo, accelerated).

Comparison Charts:

☐ Chart 1 — Direct vs. Indirect DNA Damage: Mechanism, proportion of biological effect, role of free radicals, oxygen dependence, LET dependence, and clinical significance for photon/electron versus proton/neutron therapy.

☐ Chart 2 — Low-LET vs. High-LET Radiation: Energy deposition pattern, typical LET range, dominant damage mechanism, oxygen dependence (OER), RBE, and clinical modality example for each.

☐ Chart 3 — Acute vs. Late Radiation Effects: Time of onset, tissues affected (rapidly vs. slowly proliferating), characteristic α/β ratio, reversibility, and the fractionation principle that exploits the difference. ☐ Chart 4 — Fractionation Schemes (Standard, Hyperfractionation, Hypofractionation, Accelerated): Dose per fraction, fractions per day, overall treatment time, biological rationale, and one representative clinical indication for each.

Cornell Notes:

☐ Page 1 — Cue questions: What are the Four Rs of radiobiology, and which one is the primary rationale for standard fractionation? Why does a hypoxic tumor cell require 2.5 to 3 times more low-LET dose to achieve the same kill as a well-oxygenated cell?

☐ Page 2 — Cue questions: What is the Linear-Quadratic BED formula, and how does an α/β of 3 Gy differ clinically from an α/β of 10 Gy? What does "alpha kills alone, beta brings a buddy" mean biophysically?

☐ Page 3 — Cue questions: Why are lymphocytes the most radiosensitive cell type in the body, and how does that explain early hematologic toxicity from radiation? What is the dose-response difference between acute effects (driven by total dose) and late effects (driven by fraction size), and why does this distinction dictate the fractionation design for spinal cord and lung?

Week 2 — Part 2: Radiation Physics & Technology 

Difficulty: Heavy

What it covers: Part 2 gives you the physics foundation the rest of the book and the ABR depend on — atomic structure, radioactive decay and half-life, X-ray production in a linear accelerator (bremsstrahlung and characteristic), photon and electron beam characteristics, the three dominant photon interactions with matter, proton and particle beam physics (the Bragg peak), brachytherapy source physics, radiation units, and penumbra.

Print: 1 Mind Map, 4 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Master the three photon interactions before anything else. Photoelectric dominates at low energies and depends on Z³/E³ — this is why lead shields, why bone absorbs more diagnostic kV energy than soft tissue, and why contrast agents produce their effect. Compton dominates in the therapy energy range (megavoltage), is nearly independent of Z, and depends on electron density — which is why megavoltage beams treat bone and soft tissue similarly. Pair production requires photon energy above 1.022 MeV and becomes significant above approximately 10 MeV. Every beam-physics question traces back to one of these three.

☐ Learn the linac components with the "EWB TFC MIC" mnemonic: Electron gun generates electrons by thermionic emission; Waveguide accelerates them using microwave fields from the magnetron or klystron; Bending magnet redirects the beam toward the target; Target is the high-Z material where bremsstrahlung produces X-rays; Flattening filter produces a uniform dose profile (or is removed for FFF mode); Collimators (primary, secondary jaws, MLC) shape the field; Monitor chambers measure output in real time; Interlocks prevent misdelivery; and the Control console allows treatment programming.

☐ Build a clean comparison page for photon versus electron versus proton beams. Photons penetrate deeply with a buildup region and exponential falloff, delivered by secondary electrons from Compton. Electrons deposit a relatively uniform dose to a predictable depth (therapeutic range in cm ≈ one-third of energy in MeV) then drop off sharply — ideal for superficial targets. Protons (and heavier particles) exhibit the Bragg peak, eliminating exit dose — the physical rationale for proton therapy in pediatric CNS and re-irradiation scenarios.

☐ Know the brachytherapy sources cold: Ir-192 (HDR afterloaders, half-life 73.8 days) is the workhorse. I-125 and Pd-103 are used for permanent prostate seed implants. Cs-137 is seen in older LDR intracavitary gynecologic applications. Co-60 is used in Gamma Knife SRS and some teletherapy. Know the dose-rate categories: LDR (0.4–2 Gy/hr), MDR, and HDR (>12 Gy/hr), and the representative clinical applications of each.

☐ Complete the Practice Questions for Part 2 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Radiation Physics & Technology. Main branches: Atomic Structure & Radioactive Decay → X-ray Production (bremsstrahlung, characteristic) → Linear Accelerator Components (EWB TFC MIC) → Photon Interactions (Photoelectric, Compton, Pair Production) → Photon vs. Electron vs. Proton Beams → Brachytherapy Sources & Dose Rates → Radiation Units (Gy, Sv, C/kg, Bq) → Penumbra (geometric, transmission, scatter).

Comparison Charts:

☐ Chart 1 — Photoelectric vs. Compton vs. Pair Production: Energy range of dominance, Z-dependence, probability formula, clinical significance, and the imaging or treatment modality where each matters most.

☐ Chart 2 — Photon vs. Electron vs. Proton Beams: Depth-dose curve shape, buildup region, dmax, practical range or Bragg peak, skin dose, exit dose, and the canonical clinical indication for each.

☐ Chart 3 — HDR vs. LDR Brachytherapy: Dose rate (Gy/hr), typical source, delivery device (afterloader vs. permanent implant), treatment time, radiation protection considerations, and representative clinical applications. ☐ Chart 4 — Linear Accelerator vs. Cobalt-60 vs. Orthovoltage: Radiation source, energy range, penumbra, dose rate, output stability, and clinical advantages and disadvantages of each.

Cornell Notes:

☐ Page 1 — Cue questions: What are the three dominant photon interactions, and in what energy range does each dominate clinically? How does a linear accelerator produce a therapeutic X-ray beam, and at what step does bremsstrahlung occur?

☐ Page 2 — Cue questions: What physical property of proton beams produces the Bragg peak, and why does that make proton therapy the preferred modality in pediatric CNS disease? Which brachytherapy isotopes are used for HDR afterloaders, permanent prostate seeds, and gynecologic LDR intracavitary treatment, and what dose-rate boundaries define each category?

Week 3 — Part 3: Treatment Planning Principles 

Difficulty: Heavy

What it covers: Part 3 covers the equipment and delivery technology that defines modern radiation oncology — the linear accelerator and legacy units, multileaf collimators, CT simulation and immobilization, image guidance (portal, CBCT, SGRT), IMRT and VMAT, stereotactic techniques (SRS, SBRT), proton therapy systems, brachytherapy equipment, and the quality assurance program that keeps all of it safe.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Understand what the multileaf collimator actually does. The MLC is composed of 60 to 80 opposing pairs of tungsten leaves, each 2.5 to 10 mm wide at isocenter. Static MLC shaping replaces legacy cerrobend blocks; dynamic MLC movement during delivery is the physical basis of IMRT and VMAT. Leaf position accuracy, interleaf leakage, and tongue-and-groove design are QA parameters the ABR asks about directly.

☐ IMRT, VMAT, SRS, and SBRT are not interchangeable. IMRT is static-gantry, intensity-modulated delivery used where sharp dose gradients around curved OARs matter most (head and neck is the canonical example). VMAT folds the same modulation into one or more continuous arcs with simultaneous modulation of dose rate, gantry speed, and leaf position — same conformity, faster delivery. SRS delivers ablative doses in 1 fraction (or a few) to intracranial targets with sub-millimeter precision. SBRT extends the same hypofractionated, ablative-dose principle to extracranial targets (early-stage lung 54 Gy/3 fx, liver, spine, pancreas).

☐ Image guidance closes the gap between planned and delivered dose. Portal imaging (MV) uses the treatment beam and is limited to bony verification. kV orthogonal imaging and CBCT provide 3D soft-tissue visualization for daily setup correction via the 6DOF couch. SGRT monitors the patient surface without ionizing radiation — it is ideal for intrafraction monitoring and for cardiac sparing in left-breast DIBH, but it complements, not replaces, CBCT. For motion-sensitive sites, pair image guidance with 4DCT, respiratory gating, breath-hold, or real-time tracking.

☐ Proton therapy delivery has two flavors. Passive scattering uses double-scatterers, range modulators, and patient-specific apertures to spread the Bragg peak across the target — simple but with suboptimal conformality to concave targets. Active pencil-beam scanning (PBS) magnetically steers a narrow spot across the target layer by layer, enabling intensity-modulated proton therapy (IMPT) — the most conformal proton dose distribution available and the preferred delivery for complex pediatric and skull-base cases.

☐ Quality assurance is a named system, not a vague concept. AAPM TG-40 established baseline linac QA; TG-142 updated it for IMRT, IGRT, and stereotactic capabilities (MLC leaf position ≤1 mm, stereotactic localization ≤1 mm). TG-56 governs brachytherapy QA. TG-53 covers treatment planning system commissioning. Know which report governs which equipment — the ABR tests this directly.

☐ Complete the Practice Questions for Part 3 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Radiation Equipment & Technology. Main branches: Linear Accelerator (MLC, FFF mode, 6DOF couch) → Legacy Units (Co-60, orthovoltage) → CT Simulation & Immobilization (thermoplastic masks, vacuum cushions, stereotactic frames) → Image Guidance (portal, kV/CBCT, SGRT) → IMRT & VMAT → SRS & SBRT → Proton Therapy (cyclotron/synchrotron, passive scattering vs. PBS) → Brachytherapy Equipment (HDR afterloader, LDR seeds, applicators) → Quality Assurance Programs (TG-40, TG-142, TG-56, TG-53).

Comparison Charts:

☐ Chart 1 — IMRT vs. VMAT: Delivery mechanism (static gantry vs. continuous arc), typical number of fields or arcs, treatment time per fraction, QA approach, and which clinical sites each is most commonly selected for.

☐ Chart 2 — SRS vs. SBRT: Anatomic target, typical number of fractions, dose per fraction, immobilization device, image guidance requirement, and principal clinical indication.

☐ Chart 3 — Passive Scattering vs. Pencil-Beam Scanning Proton Delivery: Beam-shaping mechanism, hardware in the beam path, dose conformality, ability to deliver IMPT, and typical clinical indication for each.

Cornell Notes:

☐ Page 1 — Cue questions: How does the multileaf collimator enable intensity modulation, and what is the difference between static MLC and dynamic MLC? What is the difference in imaging dose and soft-tissue contrast between kV CBCT and MV portal imaging, and when is each chosen?

☐ Page 2 — Cue questions: Which AAPM Task Group reports govern linac QA, brachytherapy QA, and treatment planning system commissioning — and what is the MLC leaf-position tolerance for a stereotactic-capable linac under TG-142? How does the role of SGRT complement (rather than replace) CBCT in daily image-guided treatment?

Week 4 — Part 4: CNS & Head and Neck Oncology 

Difficulty: Heavy — High Yield

What it covers: Part 4 pairs the core treatment planning framework with two of the highest-yield disease sites on the ABR. The Study Guide covers the ICRU target volume hierarchy (GTV, CTV, ITV, PTV), organ-at-risk dose constraints, dose calculation algorithms, monitor unit calculations and independent verification, dose-volume histogram analysis, adaptive radiation therapy, brachytherapy planning (TG-43 formalism), and the special techniques of TBI and TSEI. The content chapter applies this framework to glioblastoma, low-grade glioma, brain metastases, pediatric CNS tumors, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, and thyroid cancer.

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ The ICRU target volume definitions are tested directly. GTV is demonstrable disease on clinical exam, imaging, or pathology. CTV adds presumed microscopic extension — a biological margin driven by tumor patterns of spread. ITV adds internal physiological motion (applied where relevant — lung, liver). PTV adds setup and residual geometric uncertainty — a geometric margin, not a biological one. Be able to draw the nested hierarchy from memory and explain what uncertainty each margin accounts for.

☐ Build a one-page OAR dose-constraint reference for the high-yield structures: spinal cord maximum 45–50 Gy conventionally; optic chiasm and nerves 54 Gy; brainstem 54 Gy; parotid mean <26 Gy for function preservation; lung V20 <20–30% and mean lung dose <20 Gy; heart mean <26 Gy with V30 <46%; kidneys mean bilateral <18 Gy; liver mean <32 Gy with ≥700 cc under 15 Gy; rectum V70 <25%; bladder V65 <50%. These QUANTEC-derived numbers are exactly what gets tested.

☐ Dose calculation algorithms trade speed for accuracy. Pencil beam is fast but handles heterogeneity poorly — unreliable in lung-tissue interfaces. Convolution-superposition (collapsed cone) models photon scatter in three dimensions using deposition kernels — clinically acceptable for most sites. Monte Carlo tracks individual particle histories and is the gold standard for accuracy, particularly in small fields, interfaces, and electron dosimetry. In lung and head-and-neck plans, algorithm-related dose differences of 5–10% can shift coverage and OAR compliance — know which algorithm your plan uses.

☐ Learn the CNS prescriptions cold. Glioblastoma (Stupp protocol): maximal safe resection → 60 Gy in 30 fractions with concurrent temozolomide → 6–12 cycles adjuvant temozolomide. MGMT promoter methylation is the strongest predictor of TMZ benefit. Low-grade glioma (high-risk): 50.4–54 Gy + adjuvant chemotherapy (PCV or TMZ). Brain metastases: SRS for 1–4 lesions preserves neurocognition; WBRT (30 Gy in 10 fx) for diffuse disease, with hippocampal avoidance and memantine when WBRT is needed.

☐ Head and neck is the canonical IMRT indication. Definitive HNSCC: 70 Gy in 35 fractions with concurrent cisplatin for locally advanced disease. Postoperative: 60–66 Gy +/- chemotherapy for positive margins or extranodal extension. IMRT is standard because it spares the parotid glands below the 26 Gy mean-dose threshold that preserves salivary function. Nasopharyngeal carcinoma: definitive chemoradiation given the deep skull-base location and high radiosensitivity. Differentiated thyroid: surgery + I-131 is primary; external beam reserved for unresectable, iodine-refractory, or anaplastic disease.

☐ Complete the Practice Questions for Part 4 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Treatment Planning, Dosimetry & CNS/H&N Oncology. Main branches: ICRU Target Volumes (GTV, CTV, ITV, PTV) → Organs at Risk & QUANTEC Constraints → Dose Calculation Algorithms (pencil beam, convolution-superposition, Monte Carlo) → MU Calculations & Independent Verification → DVH Analysis (coverage, conformity, homogeneity indices) → Adaptive RT Triggers → Brachytherapy Planning (TG-43 formalism) → Special Techniques (TBI, TSEI) → CNS Sites (GBM/Stupp, low-grade glioma, brain mets, pediatric CNS) → Head & Neck Sites (HNSCC, nasopharyngeal, thyroid).

Comparison Charts: 

☐ Chart 1 — GTV vs. CTV vs. ITV vs. PTV: What each volume represents, what kind of uncertainty it accounts for (biological vs. geometric), how each margin is determined, and which volumes are contoured versus mathematically expanded.

☐ Chart 2 — Pencil Beam vs. Convolution-Superposition vs. Monte Carlo Algorithms: Speed, accuracy in homogeneous tissue, accuracy at tissue interfaces, typical clinical use, and one scenario where each should be avoided.

☐ Chart 3 — SRS vs. WBRT for Brain Metastases: Patient selection (number of lesions, size, KPS), target-volume definition, dose and fractionation, neurocognitive outcome, and role of hippocampal-avoidance and memantine.

☐ Chart 4 — Definitive vs. Postoperative Head and Neck Radiation: Total dose, fractionation, use of concurrent systemic therapy, typical delivery technique, and the high-risk pathology features that drive postoperative escalation.

Cornell Notes: 

☐ Page 1 — Cue questions: What is the ICRU-recommended hierarchy of GTV, CTV, ITV, and PTV, and what specific kind of uncertainty does each expansion account for? What are the QUANTEC constraints for spinal cord max, parotid mean, lung V20, heart mean, and brainstem max that every head-and-neck or thoracic plan must respect?

☐ Page 2 — Cue questions: What are the three major dose calculation algorithms, and why does algorithm choice matter more in lung and head-and-neck plans than in pelvic plans? How do you read a DVH to verify PTV coverage of V95% ≥ 95% and confirm each OAR is within constraint?

☐ Page 3 — Cue questions: What is the full Stupp protocol for glioblastoma, and what molecular marker predicts temozolomide benefit? What is the standard definitive chemoradiation prescription for locally advanced head and neck squamous cell carcinoma, and what pathologic features drive postoperative dose escalation?

Week 5 — Part 5: Thoracic & GI Oncology 

Difficulty: Heavy — High Yield

What it covers: Part 5 pairs the global disease-site framework with the thoracic and gastrointestinal cancers that dominate board exam questions. The Study Guide covers the standard-of-care approach for every major disease site — intent, technique, dose, fractionation, and role of concurrent systemic therapy. The content chapter drills into early-stage and locally advanced NSCLC (SBRT, PACIFIC), small-cell lung cancer, esophageal cancer (CROSS protocol), rectal cancer, anal cancer (Nigro protocol), pancreatic cancer, and hepatocellular carcinoma.

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Lung cancer is a multi-trial exam topic. Early-stage inoperable NSCLC: SBRT 54 Gy in 3 fractions for peripheral lesions achieves >90% local control. Locally advanced NSCLC: definitive concurrent chemoradiation to 60 Gy with platinum-based chemotherapy, followed by durvalumab consolidation — the PACIFIC regimen. Limited-stage SCLC: concurrent chemoradiation (45 Gy in 30 twice-daily fractions, or 60–70 Gy daily) followed by prophylactic cranial irradiation for responders. 4DCT and motion management drive every thoracic plan.

☐ Esophageal cancer: know CROSS. Neoadjuvant chemoradiation: 41.4–50.4 Gy with carboplatin/paclitaxel followed by surgery improves survival over surgery alone. Definitive chemoradiation: 50.4 Gy for non-surgical candidates. Pathologic complete response (pCR) is the strongest post-treatment prognostic marker.

☐ GI cancers each have a signature protocol. Rectal cancer: neoadjuvant long-course chemoradiation 50.4 Gy in 28 fractions with capecitabine or 5-FU → total mesorectal excision — or total neoadjuvant therapy (TNT) with induction chemotherapy plus short-course radiation (25 Gy in 5 fractions). Anal cancer (Nigro protocol): definitive chemoradiation to 54–59 Gy with 5-FU plus mitomycin-C — sphincter-sparing in the majority. Pancreatic cancer: SBRT 33–40 Gy in 5 fractions or conventional fractionation to 50.4 Gy for locally advanced unresectable disease. Hepatocellular carcinoma: SBRT is increasingly used when other local therapies are not feasible, exploiting the parallel-organ tolerance of the liver.

☐ Respiratory motion management is non-negotiable in the thorax and upper abdomen. 4DCT simulation acquires the tumor motion trajectory. Breath hold works for cooperative patients and provides cardiac sparing in left-sided breast. Gating delivers beam only in a chosen respiratory phase, ideal for lung tumors with >5 mm motion. Abdominal compression restricts diaphragm motion for some upper-abdominal SBRT cases. Real-time tracking follows the target during delivery.

☐ Complete the Practice Questions for Part 5 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Thoracic & GI Oncology. Main branches: Early-Stage NSCLC (SBRT 54 Gy/3 fx) → Locally Advanced NSCLC (60 Gy + chemo + PACIFIC durvalumab) → SCLC (concurrent chemoRT + PCI) → Esophageal Cancer (CROSS protocol, definitive chemoRT) → Rectal Cancer (long-course chemoRT vs. TNT) → Anal Cancer (Nigro protocol) → Pancreatic Cancer (SBRT vs. conventional) → Hepatocellular Carcinoma (SBRT) → Motion Management (4DCT, gating, breath hold, compression, tracking).

Comparison Charts:

☐ Chart 1 — Early-Stage vs. Locally Advanced NSCLC: Patient selection, treatment modality, total dose and fractionation, role of concurrent systemic therapy, role of consolidation immunotherapy (PACIFIC), and expected local control rate.

☐ Chart 2 — NSCLC vs. SCLC: Staging approach (TNM vs. limited/extensive), typical radiation role, dose and fractionation schedule, role of prophylactic cranial irradiation, and the organs at risk that dominate planning.

☐ Chart 3 — Rectal Cancer Treatment Approaches (Long-Course Chemoradiation vs. Short-Course Radiation vs. Total Neoadjuvant Therapy): Dose and fractionation, sequencing with chemotherapy, sequencing with surgery, expected pathologic complete response rate, and patient selection.

☐ Chart 4 — Respiratory Motion Management Strategies (4DCT + Gating vs. Breath Hold vs. Abdominal Compression vs. Real-Time Tracking): Principle of motion control, patient selection, typical sites used, dosimetric impact on the heart and lung, and equipment required.

Cornell Notes:

☐ Page 1 — Cue questions: What is the standard dose and fractionation for definitive SBRT in early-stage peripheral NSCLC, and what local control rate does it achieve? What is the PACIFIC regimen for locally advanced NSCLC, and at what point in the treatment course is durvalumab started?

☐ Page 2 — Cue questions: What is the CROSS protocol for esophageal cancer, and what does pathologic complete response predict? What is the dose-fractionation and systemic regimen of the Nigro protocol for anal cancer, and what clinical outcome made it the standard of care over abdominoperineal resection?

☐ Page 3 — Cue questions: What are the four primary respiratory motion management strategies, and how is each selected based on patient cooperation, tumor location, and motion amplitude? Why is 4DCT acquisition non-negotiable before planning a thoracic or upper-abdominal SBRT case?

Week 6 — Part 6: Breast, GU & Gynecologic Oncology 

Difficulty: Heavy — High Yield

What it covers: Part 6 pairs the patient-care framework with three of the most frequently tested disease domains on the ABR. The Study Guide covers the initial consultation, informed consent, psychosocial distress screening, nutritional support, the CTCAE toxicity grading system, radiation dermatitis, fatigue and pain management, and site-specific acute toxicities. The content chapter covers breast cancer (whole-breast hypofractionation, post-mastectomy indications, DIBH), prostate cancer (EBRT, SBRT, brachytherapy, the role of ADT), bladder cancer (trimodality preservation), and gynecologic cancers (cervical and endometrial EBRT plus brachytherapy).

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Breast cancer practice has shifted to hypofractionation. Adjuvant whole-breast radiation after lumpectomy: 40–42.5 Gy in 15–16 fractions is now the preferred standard. Tumor-bed boost: 10–16 Gy reduces local recurrence in high-risk patients. Post-mastectomy radiation (chest wall plus regional nodes) is indicated for tumors >5 cm, positive margins, or ≥4 positive axillary nodes. Left-sided breast: deep inspiration breath hold (DIBH) is the critical cardiac-sparing technique, typically reducing mean heart dose meaningfully and verified with SGRT.

☐ Prostate cancer shows the widest range of radiation options. Low-risk: active surveillance is often preferred. Intermediate- and high-risk: IMRT/VMAT 78–81 Gy with 4–6 or 18–36 months of ADT respectively, or SBRT 35–40 Gy in 5 fractions for favorable-risk disease, or brachytherapy (LDR seeds or HDR boost) for dose escalation within the gland. Postoperative: adjuvant or salvage radiation to the prostate bed 64–72 Gy for adverse pathology or biochemical recurrence. Rectal and bladder filling protocols drive daily reproducibility.

☐ Cervical cancer is the paradigm for combined external beam plus brachytherapy. Locally advanced (IB2 and above): definitive concurrent chemoradiation with 45 Gy external beam plus weekly cisplatin, followed by HDR or LDR brachytherapy to a total EQD2 of 80–90 Gy to the high-risk CTV. Image-guided adaptive brachytherapy using MRI has significantly improved outcomes. Endometrial cancer: adjuvant vaginal cuff brachytherapy alone for intermediate risk; pelvic external beam plus vaginal cuff brachytherapy for high risk.

☐ Radiation dermatitis progresses predictably — know the grading. Grade 1 (faint erythema, dry desquamation) appears at 2–3 weeks. Grade 2 (moderate erythema, patchy moist desquamation) at weeks 4–5. Grade 3 (confluent moist desquamation beyond skin folds) in the final weeks. Skin care protocols include gentle washing, unscented moisturizers (aqueous or calendula), avoidance of adhesive tape in-field, and loose clothing. Grade 3 moist desquamation is managed with hydrogel or hydrocolloid dressings, silver sulfadiazine for secondary infection, and possible treatment breaks. CTCAE grading drives the decision about when to hold treatment.

☐ Complete the Practice Questions for Part 6 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Breast, GU & Gynecologic Oncology + Patient Care. Main branches: Initial Consultation & Informed Consent → Distress Screening & Psychosocial Support → Nutritional Support (PEG indications in H&N) → CTCAE Grading → Radiation Dermatitis (Grades 1–3 management) → Fatigue, Pain, and Symptom Management → Breast Cancer (hypofractionation, DIBH, boost, post-mastectomy) → Prostate Cancer (IMRT + ADT, SBRT, brachytherapy, postoperative) → Bladder Cancer (trimodality preservation) → Cervical Cancer (chemoRT + brachytherapy to 80–90 Gy EQD2) → Endometrial Cancer (vaginal cuff vs. pelvic EBRT).

Comparison Charts:

☐ Chart 1 — Left-Sided vs. Right-Sided Breast Treatment: Cardiac dose risk, role of DIBH, prone vs. supine positioning considerations, nodal coverage decisions, and how SGRT enables breath-hold verification.

☐ Chart 2 — Prostate Cancer Radiation Options (EBRT + ADT vs. SBRT vs. Brachytherapy vs. Postoperative Radiation): Total dose or equivalent, fractionation, treatment duration, patient selection by risk group, and principal acute and late toxicities.

☐ Chart 3 — Cervical Cancer EBRT + Brachytherapy Boost vs. Endometrial Vaginal Cuff Brachytherapy: Indication, target volumes, dose prescription (including EQD2 summation), role of concurrent chemotherapy, and representative OAR constraints.

☐ Chart 4 — CTCAE Grades 1 vs. 2 vs. 3 Radiation Dermatitis: Appearance, typical week of treatment, skin care intervention, when to consider a treatment break, and late skin effects that may follow.

Cornell Notes:

☐ Page 1 — Cue questions: What is the current preferred adjuvant whole-breast radiation fractionation after lumpectomy, and when is a tumor-bed boost added? What is the clinical rationale for deep inspiration breath hold in left-sided breast, and which technology verifies breath-hold position during delivery?

☐ Page 2 — Cue questions: What are the four main radiation options for intermediate- and high-risk localized prostate cancer, and what duration of ADT is added for each? When is adjuvant or salvage radiation to the prostate bed indicated after prostatectomy, and what dose range is used?

☐ Page 3 — Cue questions: What is the total EQD2 target for definitive cervical cancer treatment (EBRT + brachytherapy boost), and why has image-guided adaptive brachytherapy improved outcomes? What are the three CTCAE grades of radiation dermatitis, and at which grade is a treatment break typically considered?

Week 7 — Part 7: Lymphoma, Sarcoma, Skin & Pediatrics 

Difficulty: Heavy

What it covers: Part 7 pairs the radiation safety framework with four specialized disease domains. The Study Guide covers the ALARA principle and the three cardinal protection methods (time, distance, shielding), occupational and public dose limits, vault design (primary and secondary barriers, maze, door interlocks), personnel monitoring devices, sealed-source safety and brachytherapy-specific protocols, emergency response for stuck HDR sources and lost sealed sources, and the regulatory roles of the NRC, Agreement States, FDA, DOT, and EPA. The content chapter covers Hodgkin and non-Hodgkin lymphoma (ABVD + involved-site radiation), bone and soft-tissue sarcoma, cutaneous malignancies, and pediatric tumors.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and 

Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Memorize the dose limits cold before the quiz bank. Occupational: whole-body 50 mSv/year (5 rem); lens of the eye 150 mSv/year; skin/extremities 500 mSv/year; cumulative lifetime limit = age × 10 mSv. Declared pregnant worker: 5 mSv (500 mrem) over entire gestation with a monthly ceiling of approximately 0.5 mSv. Public: 1 mSv/year (100 mrem). Patient release after I-131 or brachytherapy: dose to any individual from the released patient not likely to exceed 5 mSv (per 10 CFR 35.75). Every dose-limit question tests one of these numbers.

☐ The three cardinal protection principles — time, distance, shielding — translate into daily clinical practice. Time: minimize exposure duration. Distance: exploit the inverse square law — doubling distance reduces exposure rate to one-quarter. Shielding: primary barriers protect against the direct useful beam; secondary barriers against leakage and scatter. HVL (half-value layer) and TVL (tenth-value layer) quantify shielding — each successive HVL halves the dose. Expect vault-design questions that combine all three.

☐ Personnel dosimetry devices each have specific indications. Film badges (legacy, rarely current). OSLDs (optically-stimulated luminescent dosimeters) — re-readable, dominant current choice for body badges. TLDs (thermoluminescent dosimeters) — single-read, used for ring badges and extremity monitoring in brachytherapy. Electronic dosimeters — real-time readout for high-dose-rate environments. Know where each is worn and which quantity each measures.

☐ Lymphoma and sarcoma have their own distinctive protocols. Early-stage favorable Hodgkin lymphoma: 2–4 cycles of ABVD followed by consolidative involved-site radiation therapy (ISRT) 20–30 Gy. Low-grade NHL: 4 Gy in 2 fractions for palliation or 24–30 Gy for curative intent in limited-stage disease. Bone/soft-tissue sarcoma: limb-sparing surgery plus neoadjuvant (50 Gy) or adjuvant (60–66 Gy) radiation to preserve function.

☐ Pediatric radiation planning is a different discipline. Growth plate sparing, neurocognitive sparing, and secondary malignancy risk dominate the trade-off calculus. Proton therapy is preferred for pediatric CNS disease specifically to reduce integral dose and lifetime second-malignancy risk. Daily anesthesia is routine for children under roughly age 6. Medulloblastoma and ependymoma require craniospinal irradiation with a boost to the tumor bed — proton CSI is increasingly standard.

☐ Complete the Practice Questions for Part 7 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Radiation Safety, Protection & Lymphoma/Sarcoma/Skin/Peds. Main branches: ALARA & Three Cardinal Principles (time, distance, shielding) → Dose Limits (occupational, public, embryo/fetus, lens, extremity) → Vault Design (primary vs. secondary barriers, maze, door interlocks) → Personnel Dosimetry (film, OSLD, TLD, electronic) → Sealed-Source Safety & Brachytherapy Protocols → Emergency Response (stuck HDR source, lost source, transport accident) → Regulatory Agencies (NRC, Agreement States, FDA, DOT, EPA) → Hodgkin Lymphoma (ABVD + ISRT) → Non-Hodgkin Lymphoma → Sarcoma (neoadjuvant vs. adjuvant) → Cutaneous Malignancies → Pediatric Tumors (protons, CSI, anesthesia).

Comparison Charts:

☐ Chart 1 — Occupational vs. Public vs. Declared Pregnant Worker Dose Limits: Annual whole-body limit, lens limit, extremity/skin limit, embryo/fetus limit over gestation, and how each is verified and documented.

☐ Chart 2 — OSLD vs. TLD vs. Electronic Dosimeter: Detection mechanism, re-readability, dose range, response time, where each is worn on the body, and the clinical environment best suited to each.

☐ Chart 3 — Pediatric vs. Adult Radiation Planning Priorities: Priority organs at risk (growth plates, developing brain, gonads), preferred modality (proton vs. photon), secondary malignancy considerations, anesthesia and immobilization needs, and fractionation adjustments.

Cornell Notes:

☐ Page 1 — Cue questions: What are the annual dose limits for occupational whole-body, lens of the eye, skin/extremities, declared pregnant worker (total gestation), and members of the public? How does the inverse square law quantitatively change a therapist's exposure when they move from 1 meter to 2 meters from a source, and how do HVL and TVL govern shielding design?

☐ Page 2 — Cue questions: What are the four elements of a stuck-source emergency response in an HDR brachytherapy suite, and what is the Radiation Safety Officer's role in that response? What are the standard protocols and doses for early-stage favorable Hodgkin lymphoma, and why is proton therapy preferred for pediatric CNS tumors over photon-based treatment?

Week 8 — Part 8: Supportive Care, Toxicity & Professional Practice

Difficulty: Moderate–Heavy

What it covers: Part 8 closes the book with the professional and quality-management framework that surrounds every clinical decision. The Study Guide covers comprehensive QA programs (AAPM TG-40 and TG-142), quality improvement methodologies (PDCA, root cause analysis, FMEA), incident learning systems (RO-ILS), chart rounds and peer review, medical records and documentation, the four core ethical principles (autonomy, beneficence, non-maleficence, justice), clinical trial frameworks (IRB, NRG Oncology, phases), and emerging technologies (MR-linac, FLASH, AI). The content chapter drills into supportive care, toxicity management, and the professional practice framework.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ The four core ethical principles are tested in scenario form. Autonomy: the patient's right to make informed decisions — the legal foundation of informed consent. Beneficence: the duty to act in the patient's best interest. Non-maleficence: the duty to do no harm — why side-effect counseling is not optional. Justice: the duty to distribute care fairly. Expect a scenario that pits two principles against each other (for example, autonomy vs. beneficence in a patient refusing standard-of-care treatment) and asks which should guide the response.

☐ Quality assurance versus quality improvement is a distinction that matters. QA maintains established standards (TG-40, TG-142 for linacs; TG-56 for brachytherapy; TG-53 for TPS commissioning; gamma analysis with typical 3%/3 mm criteria for IMRT/VMAT patient-specific QA). QI actively raises those standards using PDCA (Plan-Do-Check-Act), root cause analysis after significant events, and FMEA (Failure Mode and Effects Analysis) proactively before errors occur. Know which tool is applied when.

☐ Incident learning is a national system. RO-ILS (developed by ASTRO with AAPM) provides anonymous national event reporting. The majority of radiation oncology errors originate in treatment planning and plan transfer — which is the reason for mandatory independent second-check MU calculations, systematic chart rounds, and peer review. ASTRO's APEx accreditation requires prospective peer review of a defined percentage of plans, and published studies show peer review identifies clinically significant modifications in 5–10% of reviewed plans.

☐ Emerging technologies are increasingly board-relevant. MR-linac (MRgRT) integrates real-time soft-tissue MRI with treatment delivery for on-table adaptive replanning. FLASH radiotherapy delivers ultra-high dose rates (>40 Gy/sec) with preclinical evidence of normal-tissue sparing at equivalent tumor control. AI in radiation oncology is being applied to auto-segmentation, plan optimization, QA prediction, and outcome modeling. Know the principle behind each — you do not need to know every trial.

☐ Complete the Practice Questions for Part 8 in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

☐ Mind Map: Central node = Professional Practice, Quality Management & Supportive Care. Main branches: QA Programs (TG-40, TG-142, TG-56, TG-53) → Patient-Specific QA (gamma analysis 3%/3 mm) → Quality Improvement (PDCA, RCA, FMEA) → Incident Learning Systems (RO-ILS) → Chart Rounds & Peer Review (ASTRO APEx) → Documentation & Medical Records → Four Ethical Principles (autonomy, beneficence, non-maleficence, justice) → Clinical Trials (IRB, NRG Oncology, Phase I/II/III) → Emerging Technologies (MR-linac, FLASH, AI) → Toxicity Management & Supportive Care.

Comparison Charts:

☐ Chart 1 — Quality Assurance vs. Quality Improvement: Core purpose, representative tools (TG reports and gamma analysis vs. PDCA/RCA/FMEA), when each is applied in the radiation oncology workflow, and who leads each activity.

☐ Chart 2 — Autonomy vs. Beneficence vs. Non-Maleficence vs. Justice: Definition, example of each principle in clinical action, an example scenario where two conflict, and which principle typically governs the informed-consent discussion.

☐ Chart 3 — Phase I vs. Phase II vs. Phase III Clinical Trial: Primary endpoint, typical sample size, design (dose-escalation vs. efficacy vs. comparative), and the role of the IRB and informed consent for research at each phase.

Cornell Notes:

☐ Page 1 — Cue questions: What are the four core ethical principles, and how would you apply them to a scenario in which a patient declines standard-of-care radiation for locally advanced head and neck cancer? What is the difference between QA and QI in radiation oncology, and how do PDCA, root cause analysis, and FMEA each fit in?

☐ Page 2 — Cue questions: What is RO-ILS, and where in the radiation oncology workflow do the majority of reported errors originate? What is the principle behind MR-guided radiation therapy and FLASH radiotherapy, and what clinical scenarios might each eventually change?

Week 9 — Full Review & Exam Simulation

Your final week is not about learning new material — it is about consolidating everything you have built and proving it under exam conditions.

Review Tasks

☐ Re-draw one Mind Map from memory for each Part you feel least confident about. Check it against your original.

☐ Work through your Cornell Notes cue columns for every Part — cover the right-hand notes and answer from memory.

☐ Re-do any quiz bank questions you got wrong across all Parts. Focus on the rationales.

☐ Review the 2-Minute Rapid Review and Self-Assessment Checklist sections for your two or three weakest Parts.

Exam Simulation

☐ Take the full-length ABR Radiation Oncology Board practice exam using the QR code in the back matter of this book. Complete it in one sitting, timed, as close to real exam conditions as possible.

☐ Review your emailed score report. Identify which Parts you missed most and spend your remaining time on those Parts' Rapid Review and clinical scenarios only.